



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Ku, et al.

Serial No.: 10/654,897

Filed: September 5, 2003

Title: PROCESS FOR PREPARING
AMINE-SUBSTITUTED BENZOFURANS

Case No.: 6973.US.O2

Group Art No.: 1614

Examiner: (not yet assigned)

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450 on:

Date of Deposit: January 19, 2004

Tanya Parent 1/19/04
Tanya Parent Date

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed, to the knowledge of the undersigned, before the mailing date of a first Office Action on the merits. Applicants respectfully petition and request that the Examiner consider the listed documents and evidence such consideration by making appropriate notations on the attached form. Copies of the listed documents are attached.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

The Commissioner is authorized to charge our Deposit Account any additional fees (or credit any over payments) that may be required under 37 C.F.R. §§ 1.16 and 1.17 in association with this communication for which full payment has not been tendered.

ABBOTT LABORATORIES
Customer Number 23492
Telephone: (847) 937-8272
Facsimile: (847) 938-2623

Respectfully submitted,
Ku, et al.

Portia Chen
Registration No. 44,075
Attorney for Applicants



DATE: January 16, 2004 SHEET 1_ of 1_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

6973.US.02

SERIAL NO.

10/654,897

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

APPLICANT(S)

Cowart, et al.

FILING DATE

September 5, 2003

GROUP

1614

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	INVENTOR	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

	DOCUMENT NUMBER	PUBLIC-ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION YES NO
	B1 02/74758	26.09.02	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C1	Black et al., "2,3-Diarylcyclopentenones as orally active, highly selective cyclooxygenase-2 inhibitors," J. Med. Chem. 42:1274-1281 (1999)
C2	Carroll et al., "Synthesis, nicotinic acetylcholine receptor binding, and antinociceptive properties of 2-exo-3-(2'-substituted 5'-pyridinyl)-7-azabicyclo[2.2.1]heptanes. Epibatidine analogues," J. Med. Chem. 44:2229-2237 (2001)
C3	Gronowitz et al., "On the synthesis of various thienyl- and selenienylpyrimidines," Chem. Scr. 26(2):305-309 (1986)
C4	Letsinger et al., "Organoboron compounds. IX. 8-quinolineboronic acid, its preparation and influence on reactions of chlorohydrins," J. Amer. Chem. Soc. 81(2):498-501 (1959)
C5	O'Neill et al., "Total synthesis of (±)-cytisine," Organic Letters 2(26):4201-4204 (2000)
C6	Sindkhedkar et al., "Aromatic interactions in the synthesis and conformation of two collapsible tetracationic cyclophanes," Tetrahedron 57:2991-2996 (2001)
C7	Takagi et al., "Iridium-catalyzed C-H coupling reaction of heteroaromatic compounds with bis(pinacolato)diboron: regioselective synthesis of heteroarylboronates," Tetrahedron Letters 43:5649-5651 (2002)
C8	Umemoto et al., "Molecular paneling by coordination: an M ₁₅ L ₆ hexahedral molecular capsule having clefts for reversible guest inclusion," Angew. Chem. Int. Ed. 40(14):2620-2622 (2001)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO 1449)